F Toffalorio
Overview
Explore the profile of F Toffalorio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Felip E, Shaw A, Bearz A, Camidge D, Solomon B, Bauman J, et al.
Ann Oncol
. 2021 Feb;
32(5):620-630.
PMID: 33639216
Background: Lorlatinib, a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), has substantial activity against ALK-positive non-small-cell lung cancer (NSCLC). This study assessed the overall, intracranial, and...
2.
Toffalorio F, Belloni E, Barberis M, Bucci G, Tizzoni L, Pruneri G, et al.
Br J Cancer
. 2014 Feb;
110(5):1244-9.
PMID: 24518592
Background: Classification of lung carcinoids into typical and atypical is a diagnostic challenge since no immunohistochemical tools are available to support pathologists in distinguishing between the two subtypes. A differential...
3.
Catania C, Radice D, Spitaleri G, Adamoli L, Noberasco C, Delmonte A, et al.
Psychooncology
. 2013 Oct;
23(3):322-9.
PMID: 24123459
Objective: In a previous study, we found that patients who were offered the possibility of participation in a clinical trial had unexpressed concerns and fears that prevented them from making...
4.
De Pas T, Spitaleri G, Vigna P, Toffalorio F, Curigliano G, Gambino A, et al.
Ecancermedicalscience
. 2012 Jan;
2:102.
PMID: 22275981
Background: despite the fact that the combination of gemcitabine (GCB) and docetaxel shows an increased benefit for disease-free survival and overall survival compared to GCB alone in patients with soft-tissue...
5.
De Pas T, Rosati G, Spitaleri G, Boni C, Tucci A, Frustaci S, et al.
Chemotherapy
. 2011 May;
57(3):217-24.
PMID: 21597285
Background: Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity. A phase II trial was designed to...
6.
Joensuu H, de Braud F, Grignagni G, De Pas T, Spitalieri G, Coco P, et al.
Br J Cancer
. 2011 May;
104(11):1686-90.
PMID: 21540861
Background: Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs). We report efficacy and safety results of...
7.
Catania C, Pelosi G, Fazio N, Biffi R, Spitaleri G, Noberasco C, et al.
Acta Oncol
. 2010 Jan;
49(1):120-1.
PMID: 20100147
No abstract available.
8.
Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, et al.
Pharmacogenomics J
. 2009 Nov;
10(3):180-90.
PMID: 19901957
The aim of this study was to investigate the influence of histology and site of analysis (primary tumor versus lymph node) on the expression of genes involved in gemcitabine and...
9.
De Pas T, Toffalorio F, Catania C, Noberasco C, Spitaleri G, Spaggiari L, et al.
Ann Oncol
. 2009 Aug;
20(10):1747-8.
PMID: 19690055
No abstract available.